Moreover, there are indications that the TGF-β pathway serves as a tumor suppressor in early-stage breast cancer and care must be taken when targeting TGF-β not to inhibit the tumor-suppressive role [55]. This evidence concerns the gene TGFB1 and breast carcinoma.